Subtopic Deep Dive
Imatinib Mesylate GIST Treatment
Research Guide
What is Imatinib Mesylate GIST Treatment?
Imatinib mesylate treatment for gastrointestinal stromal tumors (GIST) uses a tyrosine kinase inhibitor targeting KIT mutations to achieve sustained objective responses in advanced cases.
Clinical trials established imatinib as the standard therapy for unresectable or metastatic GIST, with over 50% response rates (Demetri et al., 2002, 4350 citations). Studies compared standard 400 mg versus higher 800 mg doses, showing no survival benefit from escalation (Blanke et al., 2008, 997 citations). Guidelines updated management protocols incorporating imatinib and resistance strategies (Demetri et al., 2010, 1209 citations).
Why It Matters
Imatinib transformed GIST from a rapidly fatal disease requiring surgery to a manageable chronic condition via targeted KIT inhibition (Demetri et al., 2002). It set the benchmark for tyrosine kinase inhibitor (TKI) therapy, enabling long-term progression-free survival in advanced cases (Blanke et al., 2008). Real-world applications include neoadjuvant therapy for resectable tumors and sequencing with sunitinib for resistance (Heinrich et al., 2008). ESMO guidelines recommend imatinib as first-line, impacting global oncology practice (Casali et al., 2018; Casali et al., 2021).
Key Research Challenges
Imatinib Resistance Mechanisms
Secondary KIT mutations emerge in GIST patients after initial response, reducing imatinib efficacy (Dêbiec-Rychter et al., 2005, 491 citations). Genotyping primary and secondary kinases correlates with sunitinib activity post-imatinib failure (Heinrich et al., 2008, 798 citations). Identifying mutation-specific therapies remains critical for prolonged control.
Optimal Dosing Strategies
Randomized trials showed higher-dose imatinib (800 mg) did not improve outcomes over standard 400 mg in KIT-expressing GIST (Blanke et al., 2008, 997 citations). Pharmacokinetic optimization balances efficacy and toxicity for long-term use. Dose adjustments for resistance lack prospective validation.
Long-Term Toxicity Management
Chronic imatinib therapy causes edema, fatigue, and myelosuppression in advanced GIST patients (Demetri et al., 2002). Guidelines emphasize monitoring for secondary malignancies and cardiac effects (Demetri et al., 2010, 1209 citations). Balancing durability against cumulative risks challenges clinical decision-making.
Essential Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · 2002 · New England Journal of Medicine · 4.3K citations
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction p...
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu et al. · 2010 · Journal of the National Comprehensive Cancer Network · 1.2K citations
The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase ...
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>
Charles D. Blanke, George D. Demetri, Margaret von Mehren et al. · 2008 · Journal of Clinical Oncology · 997 citations
Purpose The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II tri...
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich, Robert G. Maki, Christopher L. Corless et al. · 2008 · Journal of Clinical Oncology · 798 citations
Purpose Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFR...
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali, N. Abecassis, Sebastian Bauer et al. · 2018 · Annals of Oncology · 746 citations
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification
Jun Guo, Lu Si, Yan Kong et al. · 2011 · Journal of Clinical Oncology · 673 citations
Purpose Melanomas harbor aberrations in the c-Kit gene. We tested the efficiency of the tyrosine kinase inhibitor imatinib in selected patients with metastatic melanoma harboring c-Kit mutations or...
Management of malignant gastrointestinal stromal tumours
Heikki Joensuu, Christopher D.�M. Fletcher, Saša Dimitrijević et al. · 2002 · The Lancet Oncology · 567 citations
Reading Guide
Foundational Papers
Start with Demetri et al. (2002) for core efficacy data (4350 citations), then Blanke et al. (2008) for dosing results (997 citations), followed by Demetri et al. (2010) NCCN guidelines (1209 citations) to understand standards.
Recent Advances
Study Casali et al. (2018, 746 citations) and Casali et al. (2021, 499 citations) ESMO guidelines for updated follow-up and resistance strategies.
Core Methods
Core techniques include KIT/PDGFRA genotyping, RECIST response assessment, and Kaplan-Meier survival analysis in phase II/III trials.
How PapersFlow Helps You Research Imatinib Mesylate GIST Treatment
Discover & Search
Research Agent uses searchPapers and citationGraph on Demetri et al. (2002) to map 4350 citing papers, revealing resistance studies like Heinrich et al. (2008). exaSearch queries 'imatinib GIST secondary mutations' for guideline updates (Casali et al., 2021). findSimilarPapers expands from Blanke et al. (2008) dosing trial to related TKIs.
Analyze & Verify
Analysis Agent applies readPaperContent to extract response rates from Demetri et al. (2002), then verifyResponse (CoVe) cross-checks claims against Blanke et al. (2008). runPythonAnalysis plots survival curves from trial data using pandas/matplotlib. GRADE grading scores evidence as high for imatinib efficacy (Demetri et al., 2010).
Synthesize & Write
Synthesis Agent detects gaps in resistance genotyping post-Dêbiec-Rychter et al. (2005), flagging contradictions in dosing benefits. Writing Agent uses latexEditText and latexSyncCitations to draft GIST review sections citing Heinrich et al. (2008), with latexCompile for PDF output. exportMermaid visualizes KIT mutation pathways.
Use Cases
"Extract survival data from imatinib GIST trials and plot Kaplan-Meier curves"
Research Agent → searchPapers('imatinib GIST phase II') → Analysis Agent → readPaperContent(Blanke 2008) → runPythonAnalysis(pandas survival plot) → matplotlib figure of PFS/OS curves.
"Draft LaTeX review on imatinib resistance mechanisms with citations"
Synthesis Agent → gap detection(Dêbiec-Rychter 2005) → Writing Agent → latexEditText(imatinib section) → latexSyncCitations(Heinrich 2008) → latexCompile → formatted PDF manuscript.
"Find code for KIT mutation analysis in GIST imatinib studies"
Research Agent → citationGraph(Demetri 2002) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for genotype-response modeling.
Automated Workflows
Deep Research workflow scans 50+ imatinib GIST papers via searchPapers, producing structured reports with GRADE-scored efficacy data from Demetri et al. (2002). DeepScan applies 7-step CoVe analysis to resistance claims in Heinrich et al. (2008), verifying genotypes against trial outcomes. Theorizer generates hypotheses on combination TKIs from guideline evolutions (Casali et al., 2021).
Frequently Asked Questions
What defines imatinib mesylate GIST treatment?
Imatinib mesylate is a TKI targeting KIT mutations, achieving >50% objective responses in advanced GIST (Demetri et al., 2002).
What are key methods in imatinib GIST trials?
Phase II randomized dosing trials (400 vs 800 mg) and genotype correlation studies assess efficacy and resistance (Blanke et al., 2008; Heinrich et al., 2008).
What are seminal papers on imatinib GIST?
Demetri et al. (2002, 4350 citations) established efficacy; Demetri et al. (2010, 1209 citations) updated NCCN guidelines.
What open problems exist in imatinib GIST therapy?
Overcoming secondary KIT mutations and optimizing sequencing with sunitinib persist as challenges (Dêbiec-Rychter et al., 2005; Heinrich et al., 2008).
Research Gastrointestinal Tumor Research and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Imatinib Mesylate GIST Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers